11/2/2026

speaker
Dilem
Conference Operator

Good afternoon. My name is Dilem and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Inspire Medical Systems third quarter 2026 conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there'll be a question and answer session. I'll now hand the call over to your first speaker, Louisa Smith from Gilmartin Group. You may begin the conference.

speaker
Louisa Smith
Gilmartin Group

Thank you, Dilem. Joining me on today's call are Tim Herbert, Chairman and Chief Executive Officer, and Matt Osberg, Chief Financial Officer. Earlier today, we released financial results for the three months ended September 30, 2026. A copy of the press release is available on our website. On this call, management will make forward-looking statements within the meeting of federal securities laws. All forward-looking statements, including, without limitation, those relating to our operations, financial results, financial condition, investments in our business, financial and operational outlook for 2026 and future periods, and changes in market access and different aspects of coding or reimbursement are based upon our current estimates and various assumptions. Forward-looking statements involve material risks and many more. Inspire disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and speaks only as of the live broadcast today, November 2, 2026. With that, I'll turn the call over to Tim. Go ahead.

speaker
Tim Herbert
Chairman and Chief Executive Officer

Thanks, Louisa, and thank you to everyone for joining today's call. To start, the focus of our employees and the physician and care teams we work with is delivering the best possible outcomes for patients. OSA is a largely untreated condition, and the more we learn about it, the clearer it becomes that its impact goes beyond sleep to a patient's underlying health. Our Inspired Therapy is the market leader for hypoglossal nerve stimulation treatment for OSA. And we believe that better treatment leads to better sleep, which leads to better health. This belief shapes how we approach everything we do. For the third quarter, we were pleased to deliver revenue and adjusted operating income slightly ahead of our expectations with another strong quarter of operating cash flow and a 3% sequential revenue increase. Coding has been a central topic this year, so I'll provide an update using the same near, mid, and long-term lens we shared in August. In the near term, we continue to work closely with physicians and staff on the new billing procedures. As with any abrupt workflow change, It took time for implanting sites to get comfortable with the new rules. Over the last several months, centers have gained experience with a stable, temporary building framework. We expect centers to continue to use this framework and grow increasingly comfortable with it throughout 2027. For the midterm, back in July of this year, CMS announced the proposed OPPS rules for 2027 hospital and ASC reimbursement, but the final OPPS rule has not yet been released. The proposed rule in July showed a significant increase, although we will confirm only once the final rule is published, which we expect to be later this week. Longer term, we were pleased by the recently approved Category 1 CPT code for single lead hypoglossal nerve stimulation, which covers the INSPIRE-5 device. This dedicated Category 1 code is set to take effect on January 1, 2028 and stands to meaningfully simplify coding and reimbursement, thereby expanding access to INSPIRE therapy. With the code now approved, The focus shifts to the RUC valuation and reimbursement review process. This process has been started and physicians have been completing the RUC surveys sent out by the ENT Society. We will continue to provide updates as these activities progress toward the code's January 1, 2028 effective date. Overall, we are in a much more favorable position with coding then we were just last quarter and are increasingly confident in our path forward. We are very pleased with the work our internal team and external partners did to help prepare us to have the best chance of securing a new code and achieving a favorable outcome. I also want to highlight some of the exciting work we are doing in expanding our clinical evidence and how this strengthens our underlying value proposition. Recent studies and publications include the full results of the INSPIRE-5 trial, a secondary analysis of the STAR trial data, a trinetics meta-analysis, and the predictor study, all of which further support INSPIRE therapy's efficacy and positive impact on patient outcomes. We remain excited about the strong data from the early clinical assessments of INSPIRE-5 which we updated at the most recent ENT conferences, the American Academy of Otolaryngology and the International Sleep Surgical Society. The accelerometer-based sensing showed improved inspiratory overlap compared to Inspire 4, meaning more of the stimulation is synchronized with the patient's inspiration. Medium AHI also fell markedly at six months, showing a substantial reduction in the burden of disease. As we build that evidence, we are looking beyond AHI as a quantitative measure of OSA severity, which is simply the number of breathing events per hour, to hypoxic burden, which measures the overall systemic impact of oxygen deprivation during sleep. With further analysis of our STAR trial data, we saw significant reduction in hypoxic burden with Inspire Therapy and even further independent studies are now looking at how that connects to cardiovascular risk and underlying health. In the TRINETICS analysis, Inspire Therapy was associated with significantly lower odds of stroke, heart attack, and atrial fibrillation compared to a CPAP. What it tells us is that sleep apnea is not just a sleep problem. It is an overall health problem, and that is foundational for expanding access to care beyond ENTs and sleep doctors. We are early in that work, but we currently have field team resources targeting a cardiology-based call point to expand our market reach into adjacent specialties. We look forward to sharing more as this initiative develops. With the improved coding landscape, our primary commercial focus is shifting to improving patient flow. By optimizing our organizational structure and consolidating production through Project Horizon, we created approximately $30 million of annualized growth investment capacity. We are directing those funds to our highest impact revenue initiatives, which center on expanding access to care, and many more. We will continue to invest in improving patient education and engagement and helping patients navigate their treatment journey. We began making these investments in the third quarter and will further invest in the fourth quarter in order to build momentum for 2027. One example is adding field roles in approximately 40 high potential growth markets to improve and support continued growth. Further, we have made incremental marketing investments to create more targeted patient outreach and education and are continuing to enhance our prioritization process, navigator program and Inspire Connect platform to improve our patient pathway. Inspire remains the market leader in lasting OSA treatment. and we look to expand our market share. Adoption of Inspire 5 has been strong and it now makes up the vast majority of our procedures. The market remains under-penetrated with a large and growing population of patients who could benefit from our therapy. As we look to 2027, we are encouraged by how the pieces are coming together. The current coding framework is stable With a new code coming in 2028, the evidence for INSPIRE 5 continues to build and Horizon is directing resources to patient flow optimization initiatives. Improvements like these take time to move through the system, but we feel confident that much of the disruption is behind us. The coding and reimbursement path is clear and we are moving forward with conviction to drive a return to growth. With that, I'll turn the call over to Matt.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation